Abstract:Monoclonal antibody therapies targeting immuno-modulatory targets such as checkpoint proteins, chemokines, and cytokines have made significant impact in several areas, including cancer, inflammatory disease, and infection. However, antibodies are complex biologics with well-known limitations, including high cost for development and production, immunogenicity, a limited shelf-life because of aggregation, denaturation, and fragmentation of the large protein. Drug modalities such as peptides and nucleic acid aptamers showing high-affinity and highly selective interaction with the target protein have been proposed alternatives to therapeutic antibodies. The fundamental limitation of short in vivo half-life has prevented the wide acceptance of these alternatives. Covalent drugs, also known as targeted covalent inhibitors (TCIs), form permanent bonds to target proteins and, in theory, eternally exert the drug action, circumventing the pharmacokinetic limitation of other antibody alternatives. The TCI drug platform, too, has been slow in gaining acceptance because of its potential prolonged side-effect from off-target covalent binding. To avoid the potential risks of irreversible adverse drug effects from off-target conjugation, the TCI modality is broadening from the conventional small molecules to larger biomolecules possessing desirable properties (e.g., hydrolysis resistance, drug-action reversal, unique pharmacokinetics, stringent target specificity, and inhibition of protein-protein interactions). Here, we review the historical development of the TCI made of bio-oligomers/polymers (i.e., peptide-, protein-, or nucleic-acid-type) obtained by rational design and combinatorial screening. The structural optimization of the reactive warheads and incorporation into the targeted biomolecules enabling a highly selective covalent interaction between the TCI and the target protein is discussed. Through this review, we hope to highlight the middle to macro-molecular TCI platform as a realistic replacement for the antibody.

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Covalent Inhibition in Drug Discovery

Recent applications of covalent chemistries in protein-protein interaction inhibitors

Applications of covalent chemistry in targeted protein degradation

Advances in covalent drug discovery

Advanced technologies for screening and identifying covalent inhibitors

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and Targets

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond

Covalent Binding Design Strategy: A Prospective Method for Discovery of Potent Targeted Anticancer Agents.

Covalent inhibitors meet epigenetics: New opportunities

Landscape of In Silico Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery

Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality

Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions

bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements

Covalent fragment-based drug discovery for target tractability

A Comparative Clinical Pharmacology Analysis of FDA-Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Recent advances and method development for drug target identification